Drugging the Inflammasome Gasdermin Axis: Toward Precision Control of Pyroptosis

Pyroptosis, an inflammasome-driven, gasdermin-mediated form of lytic cell death, has emerged as a unifying mechanism in disorders ranging from sepsis to Alzheimer’s disease. Canonical and non-canonical pathways converge on caspase-1/4/5/11 cleavage of gasdermin D, releasing IL-1β and IL-18; basal epithelial IL-18 preserves barrier integrity, whereas unchecked cytokine efflux fuels cardiovascular, metabolic, and neuro-inflammation. Early translational successes include the oral NLRP3 inhibitor dapansutrile, which lowered synovial IL-1β by 72 % and halved pain scores in a phase II gout-flare trial, and tadekinig alfa, a recombinant IL-18-binding protein now in phase II for NLRC4-MAS. Repurposed disulfiram blocks gasdermin pores pre-clinically, while AI-guided structure screens and nanocarrier delivery are accelerating next-generation candidates. Yet inhibiting pyroptosis may heighten infection risk and demand brain-penetrant, cost-effective molecules. Judicious, biomarker-guided modulation of this fiery death program is therefore a promising but complex therapeutic strategy. This approach offers an increasingly tangible route to precision immunotherapy.